CALHM2 V136G polymorphism reduces astrocytic ATP release and is associated with depressive symptoms and Alzheimer's disease risk

作者：Yang Liao, Yingyi Wang, Qing‐Qing Tao, Chaoguang Yang, Jinlei Wang, Jinbo Cheng, Jun Ma, Zhi‐Ying Wu, Rui‐Yuan Pan, Zengqiang Yuan · 发表于：Alzheimer s & Dementia · 年份：2023 · DOI：10.1002/alz.13366 · 被引用次数：23 · 研究领域：Alzheimer's disease research and treatments、Neurotransmitter Receptor Influence on Behavior、Dementia and Cognitive Impairment Research

INTRODUCTION: Depression is considered a prodromal state of Alzheimer's disease (AD), yet the underlying mechanism(s) by which depression increases the risk of AD are not known. METHODS: Single-nucleotide polymorphism (SNP) analysis was used to determine the CALHM2 variants in AD patients. Cellular and molecular experiments were conducted to investigate the function of CALHM2 V136G mutation. We generated a new genetically engineered Calhm2 V136G mouse model and performed behavioral tests with these mice. RESULTS: CALHM2 V136G mutation (rs232660) is significantly associated with AD. V136G mutation resulted in loss of the CALHM2 ATP-release function in astrocytes and impaired synaptic plasticity. Mice homozygous for the Calhm2 V136G allele displayed depressive-like behaviors that were rescued by administration of exogenous ATP. Moreover, Calhm2 V136G mutation predisposed mice to cognitive decline in old age. DISCUSSION: CALHM2 dysfunction is a biologically relevant mechanism that may contribute to the observed clinical correlation between depression and AD.